Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in combination therapies for metastatic breast cancer
NCT02057133Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2014
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in breast cancer (13 arms), sponsored by Eli Lilly and Company. Primary endpoint: Adverse Events at 12 months. Started Mar 2014; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02057133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057133.